Carregant...

Combination Treatment With VELCADE and Low-Dose Tissue Plasminogen Activator Provides Potent Neuroprotection in Aged Rats After Embolic Focal Ischemia

BACKGROUND AND PURPOSE: Treatment with a selective proteasome inhibitor, VELCADE, in combination with tissue plasminogen activator (tPA) extended the therapeutic window to 6 hours in young rats after stroke. However, stroke is a major cause of death and disability in the elderly. The present study i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zhang, Li, Zhang, Zheng Gang, Buller, Ben, Jiang, James, Jiang, Yanting, Zhao, Danping, Liu, Xianshuang, Morris, Dan, Chopp, Michael
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2860668/
https://ncbi.nlm.nih.gov/pubmed/20203318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.109.577288
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!